NCT06809140View on ClinicalTrials.gov

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2029

Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
DRUG

Enfortumab vedotin

1.25 mg/kg (maximum dose 125 mg)

DRUG

Pembrolizumab

200 mg

Trial Locations (3)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

Matthew Galsky

OTHER